Cas:886372-88-9 6-Bromothiazolo[5,4-b]pyridine manufacturer & supplier

Chemical Name:6-Bromothiazolo[5,4-b]pyridine

CAS.NO:886372-88-9

Synonyms:6-Bromo[1,3]thiazolo[5,4-b]pyridine;Thiazolo[5,4-b]pyridine, 6-bromo-;6-bromo-[1,3]thiazolo[5,4-b]pyridine;6-Bromo-thiazolo[5,4-b]pyridine

Molecular Formula:C₆H₃BrN₂S

Molecular Weight:215.070

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:285.1±20.0 °C at 760 mmHg

Density:1.9±0.1 g/cm3

Index of Refraction:1.734

PSA:54.02000

Exact Mass:213.920029

LogP:1.74

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 6-Bromo[1,3]thiazolo[5,4-b]pyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-Bromo-thiazolo[5,4-b]pyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-Bromo[1,3]thiazolo[5,4-b]pyridine Use and application,6-Bromo-thiazolo[5,4-b]pyridine technical grade,usp/ep/jp grade.

Related News: CROS NT built up its own biometric services portfolio: clinical data management, biostatistics, statistical programming and medical writing, through a series of acquisitions in the early 2010s. In 2013, CROS NT established a foothold in the U.S. with its purchase of Stat-Tech Services, which had a presence in the medical devices sector. CROS NT followed up the next year with its buy of biometrics services provider MDSL International to broaden its U.K. branch. 6-Bromothiazolo[5,4-b]pyridine manufacturer The FDA approval allows Biogen to sell its product over several years – with forecasts for potential annual sales reaching as high $10 billion to $50 billion – until the company completes a required follow-up study. 6-Bromothiazolo[5,4-b]pyridine supplier Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. 6-Bromothiazolo[5,4-b]pyridine vendor Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. 6-Bromothiazolo[5,4-b]pyridine factory CROS NT built up its own biometric services portfolio: clinical data management, biostatistics, statistical programming and medical writing, through a series of acquisitions in the early 2010s. In 2013, CROS NT established a foothold in the U.S. with its purchase of Stat-Tech Services, which had a presence in the medical devices sector. CROS NT followed up the next year with its buy of biometrics services provider MDSL International to broaden its U.K. branch.